Literature DB >> 11568070

Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome.

H Nagashima1, Y Sakomura, Y Aoka, K Uto, M Ogawa, S Aomi, H Koyanagi, N Ishizuka, M Naruse, M Kawana, H Kasanuki.   

Abstract

BACKGROUND: Cystic medial degeneration (CMD) is a histological abnormality that is common in the aortic diseases associated with Marfan's syndrome (MFS). Although little known about the mechanism underlying CMD, several recent reports have demonstrated that vascular smooth muscle cell (VSMC) apoptosis could play a substantial role in CMD. On the other hand, angiotensin II (Ang II) has been reported to play an important role in the regulation of VSMC growth and apoptosis via the Ang II type 1 receptor (AT1R) and type 2 receptor (AT2R). METHODS AND
RESULTS: To elucidate the role of Ang II signaling via the Ang II receptors in CMD, we investigated AT1R and AT2R mRNA expression and tissue concentration of Ang II in MFS aortas (n=10) and control aortas (n=12). Furthermore, we examined the effects of an ACE inhibitor, an AT1R blocker, and an AT2R blocker on serum deprivation-induced VSMC apoptosis by organ culture system. AT1R expression was significantly decreased (P<0.01) and AT2R expression was significantly increased (P<0.001) in MFS aortas compared with control aortas, and tissue Ang II concentration was significantly higher in CMD than in the control condition (P<0.01). Both the ACE inhibitor and AT2R blocker significantly inhibited serum deprivation-induced VSMC apoptosis (P<0.05), although the AT1R blocker did not inhibit apoptosis in cultured aortic media from MFS patients.
CONCLUSIONS: Accelerated ACE-dependent Ang II formation and signaling via upregulated AT2R play a pivotal role in VSMC apoptosis in CMD, and the ACE inhibitor could have clinical value in the prevention and treatment of CMD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568070     DOI: 10.1161/hc37t1.094856

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Management of Marfan syndrome.

Authors:  John C S Dean
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

2.  Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats.

Authors:  Jian Yang; Caiyu Chen; Hongmei Ren; Yu Han; Duofen He; Lin Zhou; Ulrich Hopfer; Pedro A Jose; Chunyu Zeng
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

3.  No evidence for angiotensin type 2 receptor gene polymorphism in intron 1 in patients with coarctation of the aorta and Ullrich-Turner syndrome.

Authors:  E Struwe; K Krammer; J Dötsch; M Metzler; H G Dörr; R Cesnjevar; W Rascher; A Koch
Journal:  Pediatr Cardiol       Date:  2006-08-30       Impact factor: 1.655

Review 4.  Marfan syndrome: an update of genetics, medical and surgical management.

Authors:  Yskert von Kodolitsch; Peter N Robinson
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

5.  Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.

Authors:  Gail D Pearson; Richard Devereux; Bart Loeys; Cheryl Maslen; Dianna Milewicz; Reed Pyeritz; Francesco Ramirez; Daniel Rifkin; Lynn Sakai; Lars Svensson; Andy Wessels; Jennifer Van Eyk; Harry C Dietz
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

Review 6.  Marfan syndrome. Part 2: treatment and management of patients.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

Review 7.  Marfan syndrome. Part 1: pathophysiology and diagnosis.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

Review 8.  Aetiology and management of hereditary aortopathy.

Authors:  Aline Verstraeten; Ilse Luyckx; Bart Loeys
Journal:  Nat Rev Cardiol       Date:  2017-01-19       Impact factor: 32.419

9.  Molecular mechanisms of inherited thoracic aortic disease - from gene variant to surgical aneurysm.

Authors:  Elizabeth Robertson; Candice Dilworth; Yaxin Lu; Brett Hambly; Richmond Jeremy
Journal:  Biophys Rev       Date:  2014-12-06

10.  Medical management of aortic disease in Marfan syndrome.

Authors:  Syed Usman Bin Mahmood; Camilo A Velasquez; Mohammad A Zafar; Ayman A Saeyeldin; Adam J Brownstein; Bulat A Ziganshin; John A Elefteriades; Sandip K Mukherjee
Journal:  Ann Cardiothorac Surg       Date:  2017-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.